Advertisement
Advertisement
RCUS
Arcus Biosciences, Inc.
28.72
USDSponsored
+0.10
+0.35%
Aug 10, 16:00 UTC -4
Closed
After-Market
30.33
+1.61
+5.61%
RCUS Earnings Reports
Positive Surprise Ratio
RCUS beat 19 of 34 last estimates.
56%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$19.76M
/-$0.95
Implied change from Q2 26 (Revenue/ EPS)
-51.81%
/+31.94%
Implied change from Q3 25 (Revenue/ EPS)
-24.00%
/-25.20%
Arcus Biosciences, Inc. earnings per share and revenue
On Aug 05, 2026, RCUS reported earnings of -0.72 USD per share (EPS) for Q2 26, beating the estimate of -0.91 USD, resulting in a 21.41% surprise. Revenue reached 41.00 million, compared to an expected 23.87 million, with a 71.74% difference. The market reacted with a +2.27% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.95 USD, with revenue projected to reach 19.76 million USD, implying an increase of 31.94% EPS, and decrease of -51.81% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
MAIA Biotechnology, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-15.86%
FAQ
What were Arcus Biosciences, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Arcus Biosciences, Inc. reported EPS of -$0.72, beating estimates by 21.41%, and revenue of $41.00M, 71.74% above expectations.
How did the market react to Arcus Biosciences, Inc.'s Q2 2026 earnings?
The stock price moved up 2.27%, changed from $27.70 before the earnings release to $28.33 the day after.
When is Arcus Biosciences, Inc. expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for Arcus Biosciences, Inc.'s next earnings report?
Based on 7
analysts, Arcus Biosciences, Inc. is expected to report EPS of -$0.95 and revenue of $19.76M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement